Download Image
    
Share
  
Post
Glenzocimab for COVID-19
1 study with 62 patients
Hospital Icon Control
Hospital Icon Glenzocimab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Glenzocimab studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -60% RCTs -60% Early -60% Favorsglenzocimab Favorscontrol
Jun 17
2024
 Pottecher et al., PLOS ONE, doi:10.1371/journal.pone.0302897 Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial
RCT 61 hospitalized COVID-19 patients showing no significant difference in primary outcomes with glenzocimab (an anti-GPVI antibody) vs. placebo. Authors report glenzocimab showed a significant improvement in the NEWS-2 category at day 4,..